Sign In
Buy ARVN
$7.70
-0.300 (-3.75%)
At Close: Jun 03, 2026
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
08:35pm, Tuesday, 15'th Dec 2020
NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its P
Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates
10:32am, Tuesday, 15'th Dec 2020
Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.
Arvinas, Inc. Announces Proposed Offering of Common Stock
04:06pm, Monday, 14'th Dec 2020
NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its P
Arvinas Stock Price Doubled Today: Why It Happened
02:25pm, Monday, 14'th Dec 2020
The stock price of Arvinas Inc (NASDAQ: ARVN) doubled from $29.93 in the previous close to $60.60 as of 2:09 PM. This is why it happened.
5 Biopharma Stocks Making Big Moves Monday
11:33am, Monday, 14'th Dec 2020
Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific u
Analyzing The Price Action In Arvinas Stock Today
10:03am, Monday, 14'th Dec 2020
Arvinas (NASDAQ: ARVN) is currently up 98.06% to a price of $64.5. The stock's volume is currently 3.70 million, which is roughly 633.78% of its recent 30-day volume average of 583.25 thousand.
Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today
10:02am, Monday, 14'th Dec 2020
Arvinas (ARVN) news for Monday includes positive interim results from clinical trials sending ARVN stock soaring to new highs. The post Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today appeare
– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated pat
Arvinas to Host Webcast Presentation of New Clinical Data from ARV-471 and ARV-110 PROTAC® Protein Degrader Development Programs
04:15pm, Friday, 11'th Dec 2020
– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET –
Arvinas to Participate in Upcoming Virtual Investor Conferences
07:00am, Wednesday, 25'th Nov 2020
NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Arvinas Reports Third Quarter 2020 Financial Results and Provides Corporate Update
07:00am, Thursday, 05'th Nov 2020
– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –
ESSA's Novel Prostate Cancer Treatment In Clinical Trial: Pfizer Is New Lead Investor
11:48am, Wednesday, 19'th Aug 2020
ESSA's EPI-7386 novel approach to treat prostate cancer by targeting the N-terminal domain androgen receptor inhibitor is now in Phase 1 trials.
Arvinas to Present at the 2020 Wedbush PacGrow Virtual Healthcare Conference
11:00am, Friday, 07'th Aug 2020
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today anno
Mylan, Inc. (MYL) CEO Heather Bresch on Q2 2020 Results - Earnings Call Transcript
04:52am, Friday, 07'th Aug 2020
Mylan, Inc. (NASDAQ:MYL) Q2 2020 Results Conference Call August 06, 2020 10:30 AM ET Company Participants Melissa Trombetta - Head of Global Investor Relations Robert Coury - Chairman & Non-Execut
